Promising breast cancer combo trial pulled before it even started
NCT ID NCT07134556
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how safe they were. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zimberelimab, domvanalimab, and sacituzumab govitecan
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced triple-negative breast cancer that is PD-L1 positive.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness exist. The combination may cause significant side effects and may not work better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.